National Pension Service Has $29.95 Million Stock Position in Insulet Co. (NASDAQ:PODD)

National Pension Service lessened its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 128,664 shares of the medical instruments supplier's stock after selling 2,430 shares during the period. National Pension Service owned about 0.18% of Insulet worth $29,947,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Diversified Trust Co lifted its stake in Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock worth $1,842,000 after purchasing an additional 4,348 shares during the period. SG Americas Securities LLC lifted its stake in Insulet by 349.3% during the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier's stock worth $5,069,000 after purchasing an additional 22,993 shares during the period. Intech Investment Management LLC lifted its stake in Insulet by 113.8% during the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier's stock worth $1,140,000 after purchasing an additional 3,539 shares during the period. Natixis bought a new position in Insulet during the first quarter worth about $3,610,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Insulet during the first quarter worth approximately $1,418,000.

Insulet Stock Up 10.6 %

NASDAQ:PODD traded up $26.05 on Friday, hitting $271.03. 1,035,876 shares of the company's stock were exchanged, compared to its average volume of 779,555. The firm has a 50-day moving average price of $230.70 and a 200-day moving average price of $203.24. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. Insulet Co. has a 52 week low of $151.56 and a 52 week high of $275.52. The company has a market cap of $19.00 billion, a P/E ratio of 49.39, a price-to-earnings-growth ratio of 4.47 and a beta of 1.22.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. During the same period last year, the firm earned $0.38 earnings per share. The company's quarterly revenue was up 23.2% compared to the same quarter last year. As a group, analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on PODD. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Piper Sandler raised their price target on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. UBS Group lifted their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a report on Friday, August 9th. Citigroup lifted their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Finally, Barclays lifted their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an "equal weight" rating in a report on Monday, August 12th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $246.80.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.